To view enhanced content for this article go to http://www.medengine.com/Redeem/D7FCF0602C20A35C.
Sweden has amongst the highest incidence rates of type 1 diabetes (T1D) in Europe. The high incidence and chronic nature of T1D result in high prevalence and economic burden. Improving glycemic control reduces the incidence of microvascular complications, which in turn reduces medical costs. The present study aimed to quantify the reductions in cost and improvements in quality-adjusted life expectancy with varying reductions in HbA1c in the T1D population.
The IQVIA CORE Diabetes Model was used to simulate a typical Swedish population of patients with T1D experiencing HbA1c reductions from 0.1% to 0.8% (in 0.1% increments) from 7.9% at baseline. Analyses were conducted in simulated cohorts based on data from the Swedish National Diabetes Register (NDR) and in subgroups by sex, smoking status, and body mass index (BMI), with different sets of quality-of-life utilities included. Generalized least squares (GLS) models were used to test for significant differences between subgroups. Analyses were also performed to investigate the effect of the duration of HbA1c control. Analyses were run over 50 years and outcomes discounted at 3% per annum.
In the reference case analysis, reducing HbA1c lowered the incidence of microvascular and macrovascular complications and improved quality-adjusted life expectancy. GLS models identified a significantly larger benefit of reducing HbA1c in women over men, but found no significant differences in the magnitude of quality of life improvements with decreasing HbA1c when segregating by smoking status or BMI.
Reducing HbA1c in a population with T1D would reduce the incidence of microvascular complications, improve life expectancy and quality of life. Larger quality-of-life benefits were observed in younger and female adult patients, but no notable differences were observed in the benefits of glycemic control in smokers versus non-smokers or in patients with low or high BMI.
Novo Nordisk Scandinavia AB, Malmö, Sweden.
The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44(8):968–83. CrossRef
Nathan DM, Zinman B, Cleary PA, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications and Pittsburgh Epidemiology of Diabetes Complications Experience (1983–2005). Arch Intern Med. 2009;169:1307–16. CrossRefPubMedPubMedCentral
Cleary PA, Orchard TJ, Genuth S, DCCT/EDIC Research Group, et al. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes. 2006;55:3556–65. CrossRefPubMedPubMedCentral
Eryd AS, Svensson AM, Franzén S, Eliasson B, Nilsson PM, Gudbjörnsdottir S. Risk of future microvascular and macrovascular disease in people with type 1 diabetes of very long duration: a national study with 10-year follow-up. Diabet Med. 2016. https://doi.org/10.1111/dme.13266.
Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20(Suppl 1):S5–26. CrossRefPubMed
Ghatnekar O, Carlsson K. Kostnader för insjuknande i stroke år 2009—En incidensbaserad studie. Lund: Institutet för hälsooch sjukvårdsekonomi; 2012.
KPP database. https://skl.se/ekonomijuridikstatistik/statistik/kostnadperpatientkpp/kppdatabas.1079.html. Accessed 6 Dec 2016.
Utomlänsprislista sluten och öppen vård. 2016. https://www.sthlm-gotland.se/2016-2/. Accessed 6 Dec 2016.
Geelhoed-Duijvestijn PH, Pedersen-Bjergaard U, Weitgasser R, Lahtela J, Jensen MM, Östenson CG. Effects of patient-reported non-severe hypoglycemia on healthcare resource use, work-time loss, and wellbeing in insulin-treated patients with diabetes in seven European countries. J Med Econ. 2013;16(12):1453–61. CrossRefPubMed
Södra Regionvårdsnämnden. https://www.skane.se/templates/Page.aspx?id=228838. Accessed 6 Dec 2016.
NordDRG somatisk öppen vård 2014. https://220.127.116.11/~sthlmgot/2014-3/. Accessed 6 Dec 2016.
Pharmaceutical Benefits Board. General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2). https://www.tlv.se/Upload/English/Guidelines-for-economic-evaluations-LFNAR-2003-2.pdf. Accessed 6 Dec 2016.
Mullins P, Sharplin P, Yki-Jarvinen H, Riddle MC, Haring HU. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther. 2007;29(8):1607–19. CrossRefPubMed
Kiadaliri AA, Gerdtham UG, Eliasson B, Carlsson KS. Cost-utility analysis of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine Hagedorn basal insulin as add-on to metformin in type 2 diabetes in Sweden. Diabetes Ther. 2014;5(2):591–607. CrossRefPubMedPubMedCentral
Nathan DM, Cleary PA, Backlund JY, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643–53. CrossRefPubMed
Diabetes Control Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Mortality in type 1 diabetes in the DCCT/EDIC versus the general population. Diabetes Care. 2016;39(8):1378–83.
Woodward M, Huxley RR. Increased risk of coronary heart disease in female smokers—authors reply. Lancet. 2012;379:803. CrossRef
American Diabetes Association. 6. Glycemic Targets. Diabetes Care. 2017;40(Suppl 1):S48–56. CrossRef
National Institute for Health and Care Excellence. Technology appraisal guidance TA151. Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus. https://www.nice.org.uk/guidance/ta151. Accessed 3 April 2017.
Dornhorst A, Lüddeke HJ, Honka M, Ackermann RW, Meriläinen M, Gallwitz B, Sreenan S, PREDICTIVE Study Group. Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study. Curr Med Res Opin. 2008;24(2):369–76. CrossRefPubMed
- Achieving Good Glycemic Control Early After Onset of Diabetes: A Cost-Effectiveness Analysis in Patients with Type 1 Diabetes in Sweden
William J. Valentine
Richard F. Pollock
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
e.Med Kampagnen-Visual, Mail Icon II